Navigation Links
Amylin Pharmaceuticals Highlights New Data Supporting Therapeutic Potential of Obesity Pipeline at Obesity 2009
Date:10/19/2009

ylin/Leptin Synergy in Rodent Models" will be presented by Victoria Turek, Ph.D. at 1:00 p.m. and at 6:30 p.m. ET.
  • Poster 192-P: "Enhanced Sensitivity to Amylin-Mediated Weight Loss in Estrogen-Deficient Female Rats" will be presented by James Trevaskis, Ph.D. at 1:00 p.m. and at 6:30 p.m. ET.
  • Poster 193-P: "Impact of Sustained Amylin and/or Leptin Infusion on Energy Homeostasis, and Liver and Muscle Metabolism in Diet-Induced Obese Female Rats" will be presented by James Trevaskis, Ph.D. at 1:00 p.m. and 6:30 p.m. ET.

    • Tuesday, October 27

    • Oral Late-Breaking Clinical Trial Symposium: Steven R. Smith, M.D. will present during this symposium at 10:20 a.m. ET (ID 178416).
    • Poster 756-P: "Synergistic Anti-Obesity Effects of Optimized Amylinomimetic and PYY (3-36)-mimetic Peptides in Obese Rats" will be presented by Jonathan Roth, Ph.D. at noon and 5:30 p.m. ET.

    A full list of Amylin abstracts being presented at Obesity 2009 will be available when the final meeting program is posted at www.obesity.org/obesity2009.

    About Obesity

    Obesity is a chronic disorder that affects millions of people and is linked to increased health risk of several medical conditions including type 2 diabetes, non-alcoholic fatty liver disease, high blood pressure, heart disease, stroke, osteoarthritis, sleep disorders and several types of cancers. According to The Obesity Society, obesity is the second leading cause of preventable death in the United States. The total direct and indirect cost burden attributed to treating overweight and obesity and related conditions has grown to nearly $150 billion in the United States each year. Obesity is also rapidly becoming a major health problem in all industrialized nations and many developing countries.

    There are different classes of obesity defined by body mass index, o
    '/>"/>

    SOURCE Amylin Pharmaceuticals, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    0

    GOOD

    Page: 1 2 3 4 5

    Related medicine technology :

    1. Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity
    2. Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society
    3. Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly
    4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
    5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
    6. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
    7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
    8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
    9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
    10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
    11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/4/2009)... Dec. 4 Dynatronics Corporation (Nasdaq: DYNT ) ... provide therapy equipment and rehab supplies to Benchmark Physical ... ,, "We are pleased to be named the ... Beardall, executive vice president of sales and marketing at ...
    (Date:12/4/2009)... WASHINGTON, Dec. 4 Chemistry World recently highlighted ... Research and Manufacturers of America ( PhRMA ) that ... and related conditions. ,, The report found that ... antivirals. These drugs are either in human clinical trials or ...
    (Date:12/4/2009)... Inc. (NYSE Amex: PIP ), a biodefense ... threats, announced today that the Company is presenting ... Valortim® in an inhalation anthrax model in the ... are being presented during an oral session at ...
    Breaking Medicine Technology:U.S. Pharmaceutical Companies Developing 97 New Drugs and Vaccines to Fight HIV/AIDS 2PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 2PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 3PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 4PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 5PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 6Influenza monitoring by the US military 50914 1Influenza monitoring by the US military 50914 2Food crisis and global health workshop July 14 16 50910 1When it comes to brain damage blankets take the place of drugs 9135 1
    ... phase II/III study demonstrates C1-INH is effective treatment for ... ... 6 CSL Behring has submitted,a biologics license application (BLA) to ... C1-esterase,inhibitor concentrate in the United States for the treatment of hereditary,angioedema ...
    ... demonstrates BSGI is ... both patient and cost effective., NEWPORT NEWS, ... Bertrand, Director of Breast Imaging at Solis Bertrand Breast,Center in ... (BSGI) as an adjunctive procedure in breast,diagnostics; specifically demonstrating BSGI ...
    Other Medicine Technology:CSL Behring Submits BLA Requesting Approval of C1-Esterase Inhibitor for the Treatment of Hereditary Angioedema 2Bertrand Study Finds Significant Value in Breast-Specific Gamma Imaging (BSGI) as an Adjunctive Procedure in Breast Diagnostics 2Bertrand Study Finds Significant Value in Breast-Specific Gamma Imaging (BSGI) as an Adjunctive Procedure in Breast Diagnostics 3
    (Date:12/7/2009)... Today the Centers for Disease Control and Prevention (CDC) ... the week was designed to highlight the importance of ... of taking additional steps to keep you and your ... of December, January and beyond. ,, "It,s easy to ... topic of both seasonal and swine flu," said Dr. ...
    (Date:12/6/2009)... The University HealthSystem Consortium (UHC) recognized ... achievements in UHC,s Supply Chain Optimization Program. The ... modeling best practices in supply chain program participation. ... The winners were determined using 2008 data and ... participation and use of UHC resources. ,, Characteristics ...
    (Date:12/6/2009)... targeting growth factor, researchers say , , SUNDAY, Dec. ... cells from the main tumor to other parts of ... as TGFb, which may prove a promising target for ... say. , Previous studies have shown that TGFb (transforming ... In this new study, a team from Cancer Research ...
    (Date:12/6/2009)... Blood clotting, or coagulation, is an important process ... is injured. Sometimes, however, clots form on the ... do not dissolve naturally, a potentially life-threatening situation ... Annual Meeting of the American Society of Hematology ... aspirin and heparin with the hope of preventing ...
    (Date:12/5/2009)... in a phase 1/2 clinical trial that it ... patients newly diagnosed with multiple myeloma, a cancer of ... Dana-Farber Cancer Institute. , Partial responses or better were ... the drug combination in the multi-center study, with 74 ... the phase 2 population, reports Paul G. Richardson, MD, ...
    Breaking Medicine News(10 mins):Health News:As CDC Kicks Off National Influenza Vaccination Week, It Is More Important than Ever to Take Preventative Measures Against Cold & Flu 2Health News:As CDC Kicks Off National Influenza Vaccination Week, It Is More Important than Ever to Take Preventative Measures Against Cold & Flu 3Health News:Recognized Top Performers in UHC Supply Chain 2Health News:Breast Cancer's Spread Now Better Understood 2Health News:Three Anticoagulant Studies May Change Current Medical Practice Including New Data Revealing That Preventative Use of Aspirin and Heparin is Not Effective in Reducing Recurrent, Unexplained Miscarriages 2Health News:Three Anticoagulant Studies May Change Current Medical Practice Including New Data Revealing That Preventative Use of Aspirin and Heparin is Not Effective in Reducing Recurrent, Unexplained Miscarriages 3Health News:Three Anticoagulant Studies May Change Current Medical Practice Including New Data Revealing That Preventative Use of Aspirin and Heparin is Not Effective in Reducing Recurrent, Unexplained Miscarriages 4Health News:Three Anticoagulant Studies May Change Current Medical Practice Including New Data Revealing That Preventative Use of Aspirin and Heparin is Not Effective in Reducing Recurrent, Unexplained Miscarriages 5Health News:Three Anticoagulant Studies May Change Current Medical Practice Including New Data Revealing That Preventative Use of Aspirin and Heparin is Not Effective in Reducing Recurrent, Unexplained Miscarriages 6Health News:Three Anticoagulant Studies May Change Current Medical Practice Including New Data Revealing That Preventative Use of Aspirin and Heparin is Not Effective in Reducing Recurrent, Unexplained Miscarriages 7Health News:Multiple myeloma patients experience high response rate with new 3-drug combination 2
    ... of Blacksburg, Va., a professor of virology in the ... Sciences and Pathobiology at Virginia Tech, has been awarded ... National Institutes of Health (NIH) to study the hepatitis ... is to develop a vaccine to protect people and ...
    ... trying to quit in the future could do ... according to research from The University of Nottingham. ... which exist naturally in our bodies (endocannabinoids), are ... treating conditions as diverse as obesity, diabetes, depression ...
    ... Herley Industries,Inc. (Nasdaq: HRLY ) expects to release ... March 12, 2008., A Conference Call has been ... 2008. Interested parties may join the conference by,dialing: (888) ... the conference call is scheduled to begin on March ...
    ... BERKELEY HEIGHTS, N.J., March 7 Genta,Incorporated (Nasdaq: ... entered into an,exclusive worldwide licensing agreement with Daiichi ... commercialization of tesetaxel,(formerly known as DJ-927). As a ... activity in its initial clinical trials, and,the drug ...
    ... will soon be possible for anyone over 60 to predict ... a simple web-based tool, developed by the Sydney-based Garvan Institute ... from the end of March at www.fractureriskcalculator.com , ... five factors including sex, age, weight, history of prior fracture, ...
    ... March 7 Novavax, Inc.,(Nasdaq: NVAX ) today ... full-year financial results in a press release to be ... 2008. The Company will hold an,investor conference call to ... Friday, March 14. The call will be hosted by ...
    Other Medicine News:Health News:Human, animal vaccine development goal of hepatitis E virus research 2Health News:Human, animal vaccine development goal of hepatitis E virus research 3Health News:Curing addiction with cannabis medicines 2Health News:Herley Industries, Inc. Second Quarter Earnings Release and Conference Call Notice 2Health News:Genta Announces Licensing Agreement for Worldwide Development and Commercialization of a Leading Oral Taxane, Tesetaxel 2Health News:Genta Announces Licensing Agreement for Worldwide Development and Commercialization of a Leading Oral Taxane, Tesetaxel 3Health News:Genta Announces Licensing Agreement for Worldwide Development and Commercialization of a Leading Oral Taxane, Tesetaxel 4Health News:Launch of Web-based tool to predict risk of bone fracture 2Health News:Novavax Announces Release Date of 2007 Fourth Quarter, Full Year Financial Results and Investor Conference Call 2
    ... of Alcon Acrylic, Chiron/Iolab LI-41 and Pharmacia & ... taller and thinner, maximizing the surface area around ... during loading and insertion, and makes it easy ... lens optic. The special direct-acting jaws release the ...
    ... / Ker Accuref K 9001 ... LCD color monitor. 3 step ... 2.3 mm Minimum pupil diameter ... adjuster. Auto start function. Kerato-Peripheral ...
    ... offers accuracy, speed, ease of use, ... is an Auto Refractor/Keratometer with both ... elevation, automatic alignment, focusing, printing, high-speed ... other features that have made the ...
    Neomycin and Polymyxin B Sulfates and Hydrocortisone ophthalmic suspension is a sterile antimicrobial and anti-inflammatory suspension for ophthalmic use....
    Medicine Products: